Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy

Tauber, M.; Cohen, Romain; Laly, Pauline; Josselin, L.; Thewis, André; Mékinian, A.

doi:10.1007/s10067-018-4373-y

Cited by 17 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ir-Myositis offers some unique insights into traditional autoimmune myositides (AIM). First, if ICI are considered as a class, this "single" exposure can recapitulate a broad spectrum of AIM, including dermatomyositis 29,30,31 , necrotizing myositis 27,32 , and granulomatous myositis 33 . This supports the observation that the same exposure could be responsible for more than 1 traditional AIM.…”

Section: Immune-related Adverse Events Associated With Icimentioning

confidence: 99%

Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist

et al. 2019

View full text Add to dashboard Cite

Immune checkpoint inhibitors have revolutionized cancer therapy by blocking inhibitory pathways of the immune system to fight cancer cells. Their use is often limited by the development of autoimmune toxicities, which can affect multiple organ systems and are referred to as immune-related adverse events (irAE). Among these are rheumatologic irAE, including inflammatory arthritis, myositis, vasculitis, and others. Rheumatologic irAE seem to be different from irAE in other organs and from traditional autoimmune diseases in that they can occur early or have delayed onset, and can persist chronically, even after cancer therapy is terminated. Because immune checkpoint inhibitors are increasingly used for many types of cancer, it is important for oncologists and rheumatologists to recognize and manage toxicities early. In this review, we discuss currently approved immune checkpoint inhibitors and their mechanisms of action and systemic toxicities, with a focus on the management and effect on further cancer therapy of rheumatic irAE.

show abstract

Section: Immune-related Adverse Events Associated With Icimentioning

confidence: 99%

Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist

et al. 2019

View full text Add to dashboard Cite

show abstract

“…All other reported deaths were caused by disease progression or other causes. Despite the overall excellent tolerability, anecdotally one case of pneumonitis was reported related to pembrolizumab and we found one case report in the literature of a severe necrotizing myositis associated with long term efficacy following nivolumab and ipilimumab combination therapy [24]. Regarding atezolizumab, patients had more grade 3-4 adverse effects when combined with cobimetinib compared to atezolizumab monotherapy, but a similar rate when compared with standard of care regorafenib (61, 31 and 58%, respectively) [22].…”

Section: Safety and Securitymentioning

confidence: 75%

Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors—2020 Update

Jung

Benítez‐Ribas

Sánchez

et al. 2020

JCM

View full text Add to dashboard Cite

During the last 20 years, chemotherapy has improved survival rates of colorectal cancer (CRC). However, the majority of metastatic cases do not respond to or progress after first line conventional chemotherapy and contribute to the fatalities of patients with CRC. Insights into the immune contexture of the tumor microenvironment (TME) have enabled the development of new systemic treatments that boost the host immune system against the tumor—the immune checkpoint inhibitors (ICI). These promising drugs have already shown astonishing efficacies in other cancer types and have raised new hope for the treatment of metastatic CRC (mCRC). In this review, we will summarize the results of the clinical trials that led to their accelerated approval by the U.S. Food and Drug Administration (FDA) in 2017, as well as all relevant recent studies conducted since then—some of which are not published yet. We will focus on therapeutic efficacy, but also discuss the available data for drug safety and security, changes in quality of life indicators and predictive biomarkers for treatment response. The burgeoning evidence for a potential use of ICIs in other settings than mCRC will also be mentioned. For each trial, we have made a preliminary assessment of the quality of clinical trial design and of the “European Society of Medical Oncology (ESMO) magnitude of clinical benefit” (ESMO-MCBS) in order to provide the first evidence-based recommendation to the reader.

show abstract

“…12,39 A case report showed a 61-year old woman who received nivolumab + ipilimumab developing rapidly extending proximal muscles weakness with significant muscular oedema, enhancing the possibility of synergy in adverse events when combining ICIs. 44 Most adverse events are noted within 3 − 12 weeks of treatment, 34,45 resolving within 12 weeks of onset. 34 Some of the most common adverse events (skin rash, pruritus) can respond to antihistamines, and topical steroids, 45 which do not appear to interfere with the therapeutic effect of immunotherapy.…”

Section: Possible Adverse Effects Of Treatment With Immunotherapymentioning

confidence: 99%

PD-1 blockade as a future treatment for colorectal cancer with microsatellite instability

Russo

Barbosa

2020

Journal of Coloproctology

View full text Add to dashboard Cite

Introduction Colorectal cancer is the third most common cancer worldwide, with about 15% of these tumours related with microsatellite instability, which confers distinct characteristics to these tumours, both clinicopathological and in the response to treatments. In fact, the poor response to chemotherapy in these tumours has led to the investigation for new treatments, with immunotherapy being the most successful one to date. The focus of this review is to assess the response of microsatellite unstable colorectal cancer to PD-1 blockade, and the mechanisms behind that response. Methods A PubMed research was conducted, resulting in the inclusion of 47 articles in this review. Results Microsatellite instability results in a high neoantigen load, leading to a highly active immune microenvironment of the tumour, mainly due to T-cells. To counteract this, there is an upregulation of PD-1, acting as a “brake” for immune cells, facilitating tumour growth and metastasis. This upregulation makes these tumours great candidates for treatment with PD-1 blockade, as seen in many clinical trials, where the overall responses and progression free survival rates were higher than those observed in microsatellite stable tumours. Conclusion With the importance of colorectal cancer with microsatellite instability new treatments are necessary. Therefore, PD-1 blockade is a promising treatment for colorectal cancer with microsatellite instability, with improvement in survival rates and a better prognosis for these patients.

show abstract

Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy

Cited by 17 publications

References 7 publications

Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist

Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist

Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors—2020 Update

PD-1 blockade as a future treatment for colorectal cancer with microsatellite instability

Contact Info

Product

Resources

About